[go: up one dir, main page]

RU2001114504A - 6- (3-Acetylphenyl) aminouracil - Google Patents

6- (3-Acetylphenyl) aminouracil

Info

Publication number
RU2001114504A
RU2001114504A RU2001114504/04A RU2001114504A RU2001114504A RU 2001114504 A RU2001114504 A RU 2001114504A RU 2001114504/04 A RU2001114504/04 A RU 2001114504/04A RU 2001114504 A RU2001114504 A RU 2001114504A RU 2001114504 A RU2001114504 A RU 2001114504A
Authority
RU
Russia
Prior art keywords
compound according
brph
thiadiazol
clph
triazol
Prior art date
Application number
RU2001114504/04A
Other languages
Russian (ru)
Other versions
RU2207337C2 (en
Inventor
Елена Александровна Изаксон
Original Assignee
Елена Александровна Изаксон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елена Александровна Изаксон filed Critical Елена Александровна Изаксон
Application granted granted Critical
Publication of RU2207337C2 publication Critical patent/RU2207337C2/en
Publication of RU2001114504A publication Critical patent/RU2001114504A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (43)

1. Арил- и гетериламиды карбоалкоксисульфаниловых кислот общей формулы (1)1. Aryl and heterylamides of carboalkoxysulfanilic acids of the General formula (1)
Figure 00000001
Figure 00000001
 где R1 выбран из группы арилов и гетерилов, R2 выбран из группы алкилов.where R 1 selected from the group of aryls and heteryls, R 2 selected from the group of alkyls. 2. Соединение по п.1, отличающееся тем, что R1=4-BrPh, R2=СН3;2. The compound according to claim 1, characterized in that R 1 = 4-BrPh, R 2 = CH 3 ; 3. Соединение по п.1, отличающееся тем, что R1=4-BrPh, R2=С2Н5;3. The compound according to claim 1, characterized in that R 1 = 4-BrPh, R 2 = C 2 H 5 ; 4. Соединение по п.1, отличающееся тем, что R1=4-BrPh, R2=C4H9;4. The compound according to claim 1, characterized in that R 1 = 4-BrPh, R 2 = C 4 H 9 ; 5. Соединение по п.1, отличающееся тем, что R1=4-BrPh, R2=С5Н11;5. The compound according to claim 1, characterized in that R 1 = 4-BrPh, R 2 = C 5 H 11 ; 6. Соединение по п.1, отличающееся тем, что R1=4-BrPh, R2=С6Н13;6. The compound according to claim 1, characterized in that R 1 = 4-BrPh, R 2 = C 6 H 13 ; 7. Соединение по п.1, отличающееся тем, что R1=4-BrPh, R2=C7H15;7. The compound according to claim 1, characterized in that R 1 = 4-BrPh, R 2 = C 7 H 15 ; 8. Соединение по п.1, отличающееся тем, что R1=4-NO2Ph, R2=C4H9;8. The compound according to claim 1, characterized in that R 1 = 4-NO 2 Ph, R 2 = C 4 H 9 ; 9. Соединение по п.1, отличающееся тем, что R1=2-CH3Ph, R2=С4H9;9. The compound according to claim 1, characterized in that R 1 = 2-CH 3 Ph, R 2 = C 4 H 9 ; 10. Соединение по п.1, отличающееся тем, что R1=2-ClPh, R2=C4H9;10. The compound according to claim 1, characterized in that R 1 = 2-ClPh, R 2 = C 4 H 9 ; 11. Соединение по п.1, отличающееся тем, что R1=2,6-Cl2Ph, R2=C4H9;11. The compound according to claim 1, characterized in that R 1 = 2,6-Cl 2 Ph, R 2 = C 4 H 9 ; 12. Соединение по п.1, отличающееся тем, что R1=2-IPh, R2=C4H9;12. The compound according to claim 1, characterized in that R 1 = 2-IPh, R 2 = C 4 H 9 ; 13. Соединение по п.1, отличающееся тем, что R1=3-BrPh, R2=C4H9;13. The compound according to claim 1, characterized in that R 1 = 3-BrPh, R 2 = C 4 H 9 ; 14. Соединение по п.1, отличающееся тем, что R1=Ph, R2=C4H9;14. The compound according to claim 1, characterized in that R 1 = Ph, R 2 = C 4 H 9 ; 15. Соединение по п.1, отличающееся тем, что R1=2,5-(CH3)2Ph, R2=C4H9;15. The compound according to claim 1, characterized in that R 1 = 2,5- (CH 3 ) 2 Ph, R 2 = C 4 H 9 ; 16. Соединение по п.1, отличающееся тем, что R1=4-FPh, R2=С4H9;16. The compound according to claim 1, characterized in that R 1 = 4-FPh, R 2 = C 4 H 9 ; 17. Соединение по п.1, отличающееся тем, что R1=1,2,4-Триазол-4-ил, R2=С5Н11;17. The compound according to claim 1, characterized in that R 1 = 1,2,4-Triazol-4-yl, R 2 = C 5 H 11 ; 18. Соединение по п.1, отличающееся тем, что R1=2-СН3Ph, R2=С5Н11;18. The compound according to claim 1, characterized in that R 1 = 2-CH 3 Ph, R 2 = C 5 H 11 ; 19. Соединение по п.1, отличающееся тем, что R1=2-ClPh, R2=С5Н11;19. The compound according to claim 1, characterized in that R 1 = 2-ClPh, R 2 = C 5 H 11 ; 20. Соединение по п.1, отличающееся тем, что R1=2,6-Cl2Ph, R2=С5Н11;20. The compound according to claim 1, characterized in that R 1 = 2,6-Cl 2 Ph, R 2 = C 5 H 11 ; 21. Соединение по п.1, отличающееся тем, что R1=2-IPh, R2=С5Н11;21. The compound according to claim 1, characterized in that R 1 = 2-IPh, R 2 = C 5 H 11 ; 22. Соединение по п.1, отличающееся тем, что R1=3-BrPh, R2=С5Н11;22. The compound according to claim 1, characterized in that R 1 = 3-BrPh, R 2 = C 5 H 11 ; 23. Соединение по п.1, отличающееся тем, что R1=Ph, R2=С5Н11;23. The compound according to claim 1, characterized in that R 1 = Ph, R 2 = C 5 H 11 ; 24. Соединение по п.1, отличающееся тем, что R1=2,5-(СН3)2Ph, R2=С5Н11;24. The compound according to claim 1, characterized in that R 1 = 2.5- (CH 3 ) 2 Ph, R 2 = C 5 H 11 ; 25. Соединение по п.1, отличающееся тем, что R1=4-FPh, R2=С5Н11;25. The compound according to claim 1, characterized in that R 1 = 4-FPh, R 2 = C 5 H 11 ; 26. Соединение по п.1, отличающееся тем, что R1=2-CH3Ph, R2=СН3;26. The compound according to claim 1, characterized in that R 1 = 2-CH 3 Ph, R 2 = CH 3 ; 27. Соединение по п.1, отличающееся тем, что R1=1,2,4-Триазол-4-ил, R2=С2Н5;27. The compound according to claim 1, characterized in that R 1 = 1,2,4-Triazol-4-yl, R 2 = C 2 H 5 ; 28. Соединение по п.1, отличающееся тем, что R1=2-ClPh, R2=C7H15;28. The compound according to claim 1, characterized in that R 1 = 2-ClPh, R 2 = C 7 H 15 ; 29. Соединение по п.1, отличающееся тем, что R1=2-ClPh, R2=С6Н13;29. The compound according to claim 1, characterized in that R 1 = 2-ClPh, R 2 = C 6 H 13 ; 30. Соединение по п.1, отличающееся тем, что R1=2-СН3Ph, R2=C6H13;30. The compound according to claim 1, characterized in that R 1 = 2-CH 3 Ph, R 2 = C 6 H 13 ; 31. Соединение по п.1, отличающееся тем, что R1=2,5-(СН3)2Ph, R2=С6Н13;31. The compound according to claim 1, characterized in that R 1 = 2.5- (CH 3 ) 2 Ph, R 2 = C 6 H 13 ; 32. Соединение по п.1, отличающееся тем, что R1=Ph, R2=С6Н13;32. The compound according to claim 1, characterized in that R 1 = Ph, R 2 = C 6 H 13 ; 33. Соединение по п. 1, отличающееся тем, что R1=1,2,4-Тиадиазол-2-метил-5-ил, R2=C4H9;33. The compound according to claim 1, characterized in that R 1 = 1,2,4-Thiadiazol-2-methyl-5-yl, R 2 = C 4 H 9 ; 34. Соединение по п.1, отличающееся тем, что R1=1,2,4-Тиадиазол-2-бутил-5-ил, R2=СН3;34. The compound according to claim 1, characterized in that R 1 = 1,2,4-Thiadiazol-2-butyl-5-yl, R 2 = CH 3 ; 35. Соединение по п.1, отличающееся тем, что R1=1,2,4-Тиадиазол-2-гексил-5-ил, R2=C7H15;35. The compound according to claim 1, characterized in that R 1 = 1,2,4-Thiadiazol-2-hexyl-5-yl, R 2 = C 7 H 15 ; 36. Соединение по п.1, отличающееся тем, что R1=1,2,4-Тиадиазол-2-пентил-5-ил, R2=изоС4Н9;36. The compound according to claim 1, characterized in that R 1 = 1,2,4-Thiadiazol-2-pentyl-5-yl, R 2 = ISO 4 H 9 ; 37. Соединение по п.1, отличающееся тем, что R1=1,2,4-Тиадиазол-2-метил-5-ил, R2=СН3;37. The compound according to claim 1, characterized in that R 1 = 1,2,4-Thiadiazol-2-methyl-5-yl, R 2 = CH 3 ; 38. Соединение по п.1, отличающееся тем, что R1=1,2,4-Тиадиазол-2-бутил-5-ил, R2=С6Н13;38. The compound according to claim 1, characterized in that R 1 = 1,2,4-Thiadiazol-2-butyl-5-yl, R 2 = C 6 H 13 ; 39. Соединение по п.1, отличающееся тем, что R1=1,2,4-Триазол-4-ил, R2=С4H9;39. The compound according to claim 1, characterized in that R 1 = 1,2,4-Triazol-4-yl, R 2 = C 4 H 9 ; 40. Соединение по п. 1, отличающееся тем, что R1=1,2,4-Тиадиазол-2-пентил-5-ил, R2=СН2CF3;40. The compound according to claim 1, characterized in that R 1 = 1,2,4-Thiadiazol-2-pentyl-5-yl, R 2 = CH 2 CF 3 ; 41. Соединение по п.1, отличающееся тем, что R1=1,2,4-Тиадиазол-2-бутил-5-ил, R2=СН2CF3;41. The compound according to claim 1, characterized in that R 1 = 1,2,4-Thiadiazol-2-butyl-5-yl, R 2 = CH 2 CF 3 ; 42. Соединение по п.1, отличающееся тем, что R1=1,5-Диметил-2-Фенилпиразолон-4-ил, R2=С5Н11;42. The compound according to claim 1, characterized in that R 1 = 1,5-Dimethyl-2-Phenylpyrazolon-4-yl, R 2 = C 5 H 11 ; 43. Соединение по п.1, отличающееся тем, что R1=1,3,5-Триазин-2,4-диамино-6-ил, R2=С5Н11.43. The compound according to claim 1, characterized in that R 1 = 1,3,5-Triazin-2,4-diamino-6-yl, R 2 = C 5 H 11 .
RU2001114504/04A 1998-11-18 1998-11-18 6-(3-acetylphenyl)aminouracil RU2207337C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU1998/000387 WO2000029389A1 (en) 1998-11-18 1998-11-18 6-(3-carboxymethylphenyl)-aminouracyl having a biological activity

Publications (2)

Publication Number Publication Date
RU2207337C2 RU2207337C2 (en) 2003-06-27
RU2001114504A true RU2001114504A (en) 2004-03-20

Family

ID=20130294

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001114504/04A RU2207337C2 (en) 1998-11-18 1998-11-18 6-(3-acetylphenyl)aminouracil

Country Status (3)

Country Link
AU (1) AU2645299A (en)
RU (1) RU2207337C2 (en)
WO (1) WO2000029389A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2260590C1 (en) * 2004-04-20 2005-09-20 Тец Виктор Вениаминович 2,4-dioxo-5-(2-hydroxy-3,5-dichlorobenzylidene)imino-1,3-pyrimidine salts
RU2427373C1 (en) * 2010-11-08 2011-08-27 Виктор Вениаминович Тец Method for endogenous interferon induction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0054132B1 (en) * 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Pyrimidones, their preparation and medicines containing them
EP0517181B1 (en) * 1991-06-07 1995-09-20 Sumitomo Chemical Company Limited Amino uracil derivatives, and their production and use
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof

Also Published As

Publication number Publication date
RU2207337C2 (en) 2003-06-27
WO2000029389A1 (en) 2000-05-25
AU2645299A (en) 2000-06-05

Similar Documents

Publication Publication Date Title
RU2002109240A (en) The use of retigabin for neuropathic pain
IT1310312B1 (en) PROCESSING OF IMAGES FOR THE RECOGNITION OF ROENTGEN MEDIUM-LAYER MATERIALS.
AU8122791A (en) Benzimidazoles
RU93048636A (en) 7- / SUBSTITUTED / -8- / SUBSTITUTED / -9- / SUBSTITUTED AMINO / -6-DIMETHYL-6-DEOXYTETRACYCLINES, INTERMEDIATE COMPOUNDS, METHODS FOR PRODUCING COMPOUNDS, METHOD FOR PREVENTION AND TREATMENT
DE60211535D1 (en) PROCESS FOR THE PREPARATION OF 2,5-DIFORMYLFURAN FROM CARBOHYDRATES
RU93054537A (en) DERIVATIVES OF GUANIDINALKYL-1,1-BISPHOSPHONIC ACID, METHOD FOR PRODUCING AND USING THEM
PL368068A1 (en) Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
EP1077218A3 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
TR200001740T2 (en) Thiazole-derivatives with microbicidal and plant immunizing activities
RU2001114503A (en) Aryl- and Heterylamides of Carboalkoxy-Sulfanilic Acids
RU2001114504A (en) 6- (3-Acetylphenyl) aminouracil
DE69033086D1 (en) Process for the preparation of 5-methyl-N- (aryl) -1,2,4-triazole (1,5-a) pyrimidine-2-sulfonamides in the presence of water
RU92004359A (en) HYDRAZONES
DE60002254D1 (en) Process for the preparation of 4,6-diaminoresorcinol
DE59507509D1 (en) Process for the preparation of N, N'-carbonyldiazoles, in particular N, N'-carbonyldiimidazole
RU2002124524A (en) DERIVATIVES OF N-DEACETHILTIOCOLCHICINE AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
RU2002113084A (en) WOOD PROCESSING
DE60000274D1 (en) Process for the preparation of pirlindole hydrochloride
JP2004532837A5 (en)
TR200103562T2 (en) Rhodanine derivatives for use in the method of preventing amyloid protein aggregation and imaging amyloid deposits
DE69903610D1 (en) Process for the preparation of 5,5'-bi-1H-tetrazole salt
ATE292122T1 (en) METHOD FOR PRODUCING THE SULFONYLAMINOCARBONYL TRIAZOLINONE SALTS
HK1044702A1 (en) Treatment of osteoarthritis
ITTO990934A0 (en) HARDWARE FOR THE APPLICATION OF STORAGE BASKETS OR STORAGE TRAYS.
RU97109697A (en) BROMIDA 1 - / - FENILETHYL

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20071119

NF4A Reinstatement of patent

Effective date: 20100427

QB4A Licence on use of patent

Effective date: 20100720

QZ41 Official registration of changes to a registered agreement (patent)

Free format text: LICENCE FORMERLY AGREED ON 20100720

Effective date: 20110310